慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析*

doi:10.3969/j.issn.1672-5069.2023.02.009

摘要/Abstract

摘要： 目的探讨慢性丙型肝炎(CHC)合并非酒精性脂肪性肝病(NAFLD)患者血清视黄醇结合蛋白4(RBP4)和固醇调节元件结合蛋白-1c(SREBP-1c)水平变化及其临床意义。方法 2019年2月～2022年2月我院收治的CHC患者94例,接受肝穿刺活检和重组人干扰素-α2a联合利巴韦林治疗24周。使用全自动生化分析仪检测血生化指标,计算稳态模型胰岛素抵抗指数(HOMA-IR),采用ELISA法检测血清RBP4和SREBP-1c水平。结果经组织病理学检查发现,在94例CHC患者中,合并NAFLD患者50例(53.2%),其中肝轻度脂肪变22例(44.0%)和中重度脂肪变28例(56.0%);CHC合并中重度脂肪变患者血清AST、ALT、ALP和GGT水平分别为(62.2±12.8)U/L、(87.2±11.5)U/L、(99.0±14.4)U/L和(69.4±10.3)U/L,显著高于CHC合并轻度脂肪变患者【分别为(53.6±10.1)U/L、(75.7±12.5)U/L、(83.8±12.7)U/L和(58.5±7.7)U/L,P<0.05】或CHC患者【分别为(51.7±8.5)U/L、(73.5±13.8)U/L、(81.6±10.9)U/L和(56.2±8.1)U/L,P<0.05】;CHC合并中重度脂肪变患者血清RBP4和SREBP-1c水平分别为(55.9±8.2)mg/L和(40.1±7.4)μg/L,显著高于合并轻度脂肪变患者【分别为(36.7±5.8)mg/L和(29.3±5.1)μg/L,P<0.05】或CHC患者【分别为(28.4±6.3)mg/L和(21.8±5.5)μg/L,P<0.05】;中重度脂肪变患者血清HbA1c和HOMA-IR水平分别为(5.7±0.5)%和(3.2±0.5),显著高于CHC合并轻度脂肪变患者【分别为(5.3±0.5)%和(2.5±0.4),P<0.05】或CHC患者【分别为(5.1±0.3)%和(1.9±0.3),P<0.05】;41例治疗应答组血清RBP4和SREBP-1c水平分别为(25.7±6.0)mg/L和(20.6±5.0)μg/L,显著低于53例治疗无应答组【分别为(48.5±7.4)mg/L和(35.5±6.3)μg/L,P<0.05】。结论 CHC合并NAFLD患者血清RBP4和SREBP-1c水平升高,可能影响对干扰素-α2a抗病毒治疗的应答,值得进一步研究。

关键词: 慢性丙型肝炎, 非酒精性脂肪性肝病, 干扰素-α2a, 视黄醇结合蛋白4, 固醇调节元件结合蛋白-1c, 应答

Abstract: Objective The aim of this study was to explore the implication of serum retinol-binding protein 4 (RBP4) and sterol regulatory element-binding protein-1c (SREBP-1c) in patients with chronic hepatitis C (CHC) and non-alcoholic fatty liver diseases (NAFLD). Methods A total of 94 patients with CHC were admitted to our hospital between February 2019 and February 2022, and all underwent liver biopsy and were treated with recombinant human interferon-α 2a and ribavirin for 24 weeks. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Serum RBP4 and SREBP-1c levels were detected by ELISA. Results The liver histopathological examination revealed NAFLD in 50 cases (53.2%), including 22 (44.0%) with mild and 28 (56.0%) with moderate-severe (M/S) steatosis in our series; serum AST, ALT, ALP and GGT levels in patients with M/S steatosis were(62.2±12.8)U/L, (87.2±11.5)U/L, (99.0±14.4)U/L and (69.4±10.3)U/L, much higher than [(53.6±10.1)U/L, (75.7±12.5)U/L, (83.8±12.7)U/L and (58.5±7.7)U/L, respectively, P<0.05] in patients with mild steatosis or [(51.7±8.5)U/L,(73.5±13.8)U/L,(81.6±10.9)U/L and (56.2±8.1)U/L, respectively, P<0.05] in patients with CHC; serum RBP4 and SREBP-1c levels in patients with M/S steatosis were (55.9±8.2) mg/L and (40.1±7.4)μg/L, significantly higher than [(36.7±5.8)mg/L and (29.3±5.1)μg/L, respectively, P<0.05] in patients with mild steatosis or [(28.4±6.3)mg/L and (21.8±5.5)μg/L, P<0.05] in patients with CHC; serum HbA1c and HOMA-IR in patients with M/S steatosis were (5.7±0.5)% and (3.2±0.5), both significantly higher than [(5.3±0.5)% and (2.5±0.4), P<0.05] in patients with mild steatosis or [(5.1±0.3)% and (1.9±0.3), P<0.05] in patients with CHC; serum RBP4 and SREBP-1c levels in 41 patients who responded to interferon-α 2a therapy were (25.7±6.0)mg/L and (20.6±5.0)μg/L, much lower than [(48.5±7.4)mg/L and (35.5±6.3)μg/L, P<0.05] in 53 patients who didn’t. Conclusion Serum RBP4 and SREBP-1c levels in patients with CHC and NAFLD increase, which might interferes with antiviral therapy, and warrants further investigation.

Key words: Hepatitis C, Non-alcoholic fatty liver diseases, Interferon-α 2a, Retinol-binding protein 4, Sterol regulatory element-binding protein-1c, Response

范明芳, 田瑛, 周倩, 接贵涛, 刘淑芳. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 185-188.

Fan Mingfang, Tian Ying, Zhou Qian, et al.. Changes of serum RBP4 and SREBP-1c levels in patients with chronic hepatitis C and non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(2): 185-188.

参考文献

[1] Koch LK, Yeh MM. Nonalcoholic fatty liver disease (NAFLD): diagnosis, pitfalls, and staging. Ann Diagn Pathol, 2018, 37(1): 83-90.
[2] Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: why does it really matter? Gut, 2006, 55(1): 123-130.
[3] Cheng FK, Torres DM, Harrison SA. Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? J Viral Hepat, 2014, 21(1): 1-8.
[4] 莫超艳, 杨有强, 钟嫄, 等. 非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨. 实用肝脏病杂志, 2022, 25(2): 231-234.
[5] Petta S, Cammà C, Di Marco V, et al. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. Hepatology, 2008, 48(1): 28-37.
[6] Jackel-Cram C, Qiao L, Xiang Z, et al. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway. J Gen Virol, 2010, 91(6): 1388-1395.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1): 33-52.
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018, 21(2): 177-186.
[9] Toyoda H, Kumada T, Kiriyama S, et al. Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C. Cytokine, 2013, 63(2): 145-150.
[10] Dyal HK, Aguilar M, Bhuket T, et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients: a systematic review. Dig Dis Sci, 2015, 60(9): 2813-2824.
[11] 张晓伟, 钟蕊. 索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察. 实用肝脏病杂志, 2020, 23(2): 191-194.
[12] Kilicarslan M, Weijer BA, Simonyte Sjodin K, et al. RBP4 increases lipolysis in human adipocytes and is associated with increased lipolysis and hepatic insulin resistance in obese women. FASEB J, 2020, 34(5): 6099-6110.
[13] Kloting N, Graham TE, Berndt J, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metabol, 2007, 6(1): 79-87.
[14] Steinhoff JS, Lass A, Schupp M. Retinoid homeostasis and beyond: how retinol binding protein 4 contributes to health and disease. Nutrients, 2022, 14(6): 1236.
[15] 刘滨菘, 李强, 王薇, 等. 视黄醇结合蛋白4与非酒精性脂肪肝病的相关研究. 中华内分泌代谢杂志, 2013, 29(1): 58-61.
[16] Zhang ZH, Ke JF, Lu JX, et al. Serum retinol-binding protein levels are associated with nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus: a real-world study. Diabetes Metab J, 2022, 46(1): 129-139.
[17] Stefan N, Hennige AM, Staiger H, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care, 2007, 30(5): 1173-1178.
[18] 杨朝霞, 孙航, 沈薇. 非酒精性脂肪性肝病患者肝脏固醇调节元件结合蛋白-1c的表达及其意义. 中华肝脏病杂志, 2008, 16(11): 823-826.
[19] Nguyen TTP, Kim DY, Lee YG, et al. SREBP-1c impairs ULK1 sulfhydration-mediated autophagic flux to promote hepatic steatosis in high-fat-diet-fed mice. Mol Cell, 2021, 81(18): 3820-3832.
[20] Lucero D, Miksztowicz V, Macri V, et al. Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α. Clin Investig Arterioscler, 2015, 27(4): 167-174.

慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*

Changes of serum RBP4 and SREBP-1c levels in patients with chronic hepatitis C and non-alcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[2]	郝蕾, 高卫东, 胡娟娟, 张琳, 邢亚恒. 非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 189-192.
[3]	方颖, 金家东, 汪芾, 周达. 新冠疫情期间情绪对非酒精性脂肪性肝病患者血生化指标的影响^*[J]. 实用肝脏病杂志, 2023, 26(2): 193-196.
[4]	刘岗, 张浩, 胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 197-201.
[5]	李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.
[6]	黄淡霞, 招志辉, 萧月兴, 何艳青. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
[7]	陈凤莲, 朱青蓝, 朱伶俐, 陈国飞. 非酒精性脂肪性肝病患者外周血恒定自然杀伤T细胞和CD4⁺/CD8⁺T细胞活化差异研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 31-34.
[8]	徐伟强, 刘淑萍, 李潇萌. 体检人群非酒精性脂肪性肝病检出率及其危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 35-38.
[9]	陈怡, 朱友, 周希乔. 甲状腺激素与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 145-148.
[10]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[11]	吴凤萍, 崔丹丹, 王怡恺, 李梅, 刘晨瑞, 南希, 贾晓黎, 党双锁. 血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 780-783.
[12]	齐孝安, 卢金喜, 袁林. 慢性乙型肝炎患者降钙素基因相关肽和α-干扰素-λ4基因多态性对α-干扰素治疗应答的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 784-787.
[13]	许海玲, 秦刚, 薛红, 章颖. 艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 788-791.
[14]	孙峥, 王笑烨, 袁景, 梁丽. 达格列净联合利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 796-799.
[15]	蔡勇, 李璟, 欧琴. 2型糖尿病合并非酒精性脂肪性肝病患者血清网膜素、视黄醇结合蛋白4和Ⅰ型原胶原氨基端前肽水平及意义分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 800-803.